Fifty-seven patients receiving unrelated donor (UD) BMT were matched for disease and stage with 57 recipients of genotypically matched related donor (MRD) BMT. All UD recipients were matched serologically for A and B and by high resolution for DR and DQ antigens. All patients received CsA and 'short course' methotrexate with folinic acid. Unrelated donor BMT patients also received thymoglobulin 4.5 mg/kg (6 mg/kg if Ͻ30 kg) in divided doses over 3 days pretransplant. For UD and RD BMT, respectively, incidence of acute GVHD grade II-IV was 19 ؎ 6% vs 36 ؎ 8%, grade III-IV 10 ؎ 6% vs 18 ؎ 7%, chronic GVHD 44 ؎ 8% vs 51 ؎ 8%, non-relapse mortality 15 ؎ 5% vs 8 ؎ 4% at 100 days, 28 ؎ 8% vs 36 ؎ 7% at 3 years. At 3 years, relapse was 45 ؎ 7% vs 42 ؎ 7%, and disease-free survival 39 ؎ 7% vs 37 ؎ 7%. None of these differences are significant. Three-year overall survival was identical at 42 ؎ 7%. For 29 patients with low/intermediate risk leukemia, disease-free survival was 68 ؎ 10% after UD BMT vs 59 ؎ 9% for RD BMT recipients (P = NS). Corresponding figures for high risk patients were 14 ؎ 7% and 21 ؎ 8%, respectively. We conclude that UD BMT recipients matched as above and given pretransplant ATG have similar outcomes to recipients of MRD BMT using conventional drug prophylaxis. Unrelated donor BMT should be considered in any circumstance where MRD BMT is routine.
In recent years outcomes of BMT from unrelated donors (UD) have improved, in part because of more sophisticated tissue typing and perhaps also better supportive care. [1] [2] [3] [4] [5] [6] In addition, some uncontrolled studies have indicated that pretransplant serotherapy with antithymocyte globulin (ATG) or other antibodies appears to reduce acute GVHD and early mortality of closely matched UD BMT to levels comparable to matched related donor (MRD) BMT. [7] [8] [9] [10] [11] [12] [13] [14] [15] Since 1995 we have used a relatively low dose of rabbit ATG in the pretransplant conditioning protocol for all UD transplants. Outcomes of 57 of these patients are compared with those of 57 MRD BMT recipients matched for important prognostic factors.
Patients and methods

Patients
Since May 1995 all UD stem cell transplant recipients received pretransplant ATG as described below. Satisfaction of additional criteria was required for inclusion in this study. Unrelated donors had to be matched serologically for A and B antigens and by high resolution DNA based typing for DR␤1 and DQ␤1. Recipients had to have received bone marrow as the stem cell source, and to have a control MRD transplant recipient matched for at least disease and stage of disease. Of 93 patients transplanted until October 2000, 57 satisfied these criteria. Three received blood cells, nine were mismatched and the remaining 24 could not be matched because of insufficient control patients with the same diagnosis and disease stage. The control group comprised 57 of the 153 recipients of bone marrow from genotypically matched sibling donors treated between September 1987 and December 1998 using the same GVHD prophylaxis with MTX and CsA. After this time all MRD transplant recipients also received ATG. If more than one MRD recipient satisfied the above criteria selection was based in sequence on age group (below 18, 18 and above), conditioning protocol (TBI based or not) and finally closeness of age. All patients were receiving their first BMT.
UD recipients were aged 2-55 (median 32), the MRD group were 6-54, median 33. Some details of diagnosis are recorded in Table 1 . Patients with advanced acute leukemia with myeloid features (AML arising from MDS, refractory biphenotypic leukemia and relapsed/refractory AML) were grouped together. Unrelated donor BMT survivors have been followed for 16 to 76 months (median 34), the period for MRD BMT survivors is 49-158 months, median 104.
Treatment
All but two patients were nursed without protective isolation. 16 Blood products were all from CMV seronegative donors. Single donor platelets were given to maintain counts Ͼ10 ϫ 10 9 /l and red cells to keep hemoglobin levels Ͼ80 g/l. Growth factors were not given routinely. Antibacterial and antipneumocystis prophylaxis comprised either twice daily trimethoprim/sulfamethoxazole (14 UD, 32 RD) or ciprofloxacin 500 mg twice daily and twice weekly trimethoprim/sulfamethoxazole. Prophylactic ganciclovir 5 mg/kg i.v. three times weekly was given to recipients of UD BMT when donor and/or recipient were CMV seropositive, no systemic antifungal prophylaxis was used routinely. The acute GVHD prophylaxis protocol included CsA orally or intravenously twice daily to maintain blood levels between 250 and 400 mol/l. Methotrexate was given in doses of 15 mg/m 2 i.v. on day 1 and 10 mg/m 2 on days 3, 6 and 11. Folinic acid 5 mg i.v. or p.o. was started 24 h after each dose of methotrexate and continued every 6 h until 12 h before the next dose. 17 Rabbit ATG (thymoglobulin; Sangstat, Fremont, CA, USA) 4.5 mg/kg was given in divided doses over 3 days to UD BMT recipients unless they weighed less than 30 kg in which case the total dose was 6 mg/kg. In order to reduce reactions, the most recent cohort of 39 adults received 0.5 mg/kg on the first infusion followed by two doses of 2 mg/kg; in the remainder all three doses were equal. Each dose was given as a continuous i.v. infusion over 4-6 h. The final infusion was given on day Ϫ1 or the day of transplant. Premedication with methyprednisolone 40 mg i.v. 12 h for six doses and benadryl 50 mg i.v. before each dose of ATG was given, with doses adjusted in children.
Engraftment
Daily blood counts were done until discharge with bone marrow aspirations at 3 months for surviving patients and as clinically indicated. Granulocyte engraftment was defined as a count of Ͼ0.5 ϫ 10 9 /l. The platelet count needed to be above 20 ϫ 10 9 /l without transfusion for 3 days. Patients dying within 28 days were considered unevaluable for engraftment. Failure of neutrophil or platelet levels to recover by day 42 in the absence of persistent malignancy or other apparent cause was considered as graft failure.
Graft-versus-host disease
Graft-versus-host disease was graded according to standard criteria. 18 
Statistical analysis
Fisher's exact test was applied to distribution of numerical differences between groups. The distributions of time to events were compared using the logrank test, with patients being censored for relapse for estimation of non-relapse mortality. Analysis was performed on a Macintosh computer using GraphPad Prism software (GraphPad Corp., San Diego, CA, USA).
Results
Immediate Toxicity
Despite premedication the first infusion of ATG was frequently accompanied by fever and chills. There were no severe immediate sequelae and serum sickness was not seen. Reactions were generally absent or less severe with the second and third doses.
Engraftment
One UD BMT recipient was not evaluable for engraftment because of early death. Six of the remaining 56 did not recover neutrophils, three because of persistent disease. Two died without engraftment, the other received a successful second stem cell infusion. An additional eight UD recipients failed to achieve platelet recovery. This was attributed to persistent or relapsed leukemia in three, transplantrelated causes in four and primary failure to engraft in one.
In the MRD group engraftment was unevaluable in two because of early death. Of the remainder, all engrafted neuBone Marrow Transplantation trophils but nine had no platelet recovery accounted for by persistent disease (five) or transplant-related causes leading to death from 35 to 130 days post-transplant (four).
Of the four UD BMT patients considered to have primary graft failure (of platelets alone in one, neutrophils and platelets in three) all had suboptimal (Ͻ2.0 ϫ 10 8 /kg) doses of nucleated cells in the graft. The doses were 0.77, 0.81, 0.89 and 1.18 ϫ 10 8 /kg. In those patients with hematologic recovery, median time to neutrophil engraftment was 20 days (range 8-95) for UD vs 24 days (range 16-106) for MRD BMT recipients. For platelets, the median was 24 days in both groups (ranges 14-204 for UD, 14-42 for MRD).
Graft-versus-host disease
The actuarial incidence of acute GVHD grades II-IV was 19 Ϯ 6% in UD recipients compared with 36 Ϯ 8% after MRD BMT (Figure 1a) . The figures for grade III-IV disease were 10 Ϯ 6% and 18 Ϯ 7%, respectively (Figure 1b) . At 3 years the projected incidence of chronic GVHD was 44 Ϯ 8% for UD and 51 Ϯ 8% for MRD BMT ( Figure  1c) . None of these differences are statistically significant.
Relapse
By 3 years the projected relapse rates were very similar, 45 Ϯ 7% in the UD group vs 42 Ϯ 7% after MRD BMT (Figure 2a) .
Transplant-related mortality
At 100 days actuarial non-relapse mortality was 15 Ϯ 5% for UD and 8 Ϯ 4% for MRD recipients (P = NS, Figure  2b ). At 3 years the figures were 28 Ϯ 8% and 36 Ϯ 7%, respectively. Table 2 gives the causes of early and later transplant-related death.
Disease-free survival (DFS) and overall survival (OS)
At 3 years DFS in UD BMT recipients was 39 Ϯ 7% vs 37 Ϯ 7% after MRD BMT (Figure 3a) . Figures for OS were identical at 42 Ϯ 7% (Figure 3b) . For low/intermediate risk patients DFS was 68 Ϯ 10% after UD BMT vs 59 Ϯ 9% for RD BMT recipients. Corresponding figures for high risk patients were 11 Ϯ 6% and 14 Ϯ 7%, respectively ( Figure  4a ). Overall survival was 68 Ϯ 10% after UD BMT vs 62 Ϯ 9% for RD BMT recipients with low/intermediate risk disease. For high risk disease OS was 14 Ϯ 7% after UD BMT and 21 Ϯ 8% after MRD BMT (Figure 4b ). None of these outcomes differ significantly.
Discussion
While the genotypically MRD has been considered the 'gold standard' for donors, volunteer UD provide an alternative source in about 25% of all allogeneic transplants reported by the International Bone Marrow Transplant Registry (IBMTR). 19 Not only are transplants from UD more expensive, they have been viewed as more compli- cated and leading to inferior outcomes, particularly in low and intermediate risk disease. 19 Even in the years from 1991 to 1997, data submitted to the IBMTR indicated that patients with early CML, for example, had survivals 15-20% better with MRD than with UD. However, recent data from single institutions have shown outcomes after UD BMT approaching those achieved from MRD transplants. 1, 8, 11 These improved results appear to be at least partly due to improved matching techniques. For example, both acute GVHD and TRM are significantly less after transplants from UD matched by molecular methods for class II antigens.
2-5 Nevertheless, even patients matched by these techniques with their donors for both class I and class 
Table 2
Causes of non-relapse death
Death before day 100 Death after day 100 Total deaths UD GVHD/CMV (1) Chronic GVHD (3) 11 (n = Graft failure (2) PTLD (after 2nd transplant 57)
PTLD (1) for graft failure) (1) GVHD/HUS/PTLD (1) Candidiasis (1) Viral infection (1) MRD ARDS (1) Chronic GVHD (9) (one 16 (n = Multiorgan failure (1) with PTLD) 57)
HUS with hemorrhage (1) II antigens may have acute GVHD grade III-IV over 30% when receiving conventional prophylaxis with MTX and CsA.
2 This high morbidity from acute GVHD probably accounts at least partly for any apparent inferiority of UD transplants with respect to both ease of management and final outcomes. Attempts to improve these results by T cell depletion of the transplanted cells have met with limited success. While acute GVHD can be ameliorated the benefits are often offset by increased rates of graft failure, opportunistic infection and relapse. 6 In recent years, a number of European centers have reported relatively low rates of acute GVHD and early TRM using a variety of ATG products and schedules of administration. [7] [8] [9] [10] [11] [12] [13] [14] [15] Total doses of pretransplant thymoglobulin have ranged between 8 and 20 mg/kg. 8, 9, 12, 13 An IBMTR analysis of alternative donor transplants between 1987 and 1993 indicated that the influence of donors on outcome was not apparent in high risk patients but quite significant with low and intermediate risk disease. 20 The current analysis indicates that equivalent outcomes may be seen at all stages. Some potential shortcomings of this study must be addressed. First, it was necessary to search our database back to 1987 in order to find as many MRD BMT as possible for the matched control group. This was because of the limited number of patients undergoing BMT rather than BCT after our practices began to change in 1993. However, the support protocols have remained relatively consistent and we have no evidence that outcomes of MRD transplants have improved significantly within this time frame. 16 Although there were some differences in conditioning protocols, the regimenrelated toxicity appears similar between i.v. and p.o. busulfan and also between cyclophosphamide and fludarabine when combined with busulfan. 21, 22 Finally, it might be argued that using bone marrow rather than blood cells is no longer 'state of the art' for some indications. While this may be the case, evaluation of the impact of ATG on GVHD in particular is possible only if the same cell source is used and we maintain that conclusions regarding the relative tolerability of BMT from UD remain valid. Sometimes different approaches may result in similar outcomes because, for example, death from relapse is compensated for by less TRM from GVHD. An intriguing finding in this study is that all causes of morbidity and mortality, ie GVHD, relapse and TRM are very similar. It seems that the use of ATG in the UD recipients somehow compensates for the disparity of the UD so that these recipients behave clinically like MRD recipients not given ATG.
In conclusion, we suggest that this regimen of pretransplant ATG given to recipients of UD BMT results in similar outcomes to those expected using MRD. It is our view that any indication for MRD BMT also applies to UD BMT from a closely matched donor. Finally, from the patient's perspective it should be comforting to know that an appropriately matched UD should not be seen as 'second best' with respect to the final result.
